STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

GS Group and Goldman Sachs & Co. LLC disclose joint NVRO holding of 1,172 shares

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC jointly reported beneficial ownership of 1,172 shares of Nevro Corp. common stock, representing 0.0% of the class. The filing shows shared voting power of 905 shares and shared dispositive power of 1,172 shares, with no sole voting or dispositive power recorded.

The Schedule 13G/A states these holdings are reported as held in the ordinary course of business and not for the purpose of influencing control. The filing also discloses that Goldman Sachs & Co. LLC is a subsidiary of The Goldman Sachs Group, Inc., and the parties executed a joint filing agreement documenting the joint submission.

Positive

  • Clear joint filing and parent-subsidiary disclosure clarifying the relationship between the reporting entities
  • Holdings reported as held in the ordinary course of business, not for control, reducing governance concerns

Negative

  • None.

Insights

Small, non-controlling position; routine disclosure with negligible market impact.

The filing quantifies a very small stake of 1,172 shares in NVRO, equal to 0.0% of the outstanding class, with 0 shares held with sole voting or dispositive power and 905 shares reported as shared voting power. This scale of ownership is immaterial to company control or earnings expectations and is consistent with brokerage or advisory activities. The explicit statement that the shares are held in the ordinary course and not to influence control reduces regulatory and governance concerns for investors.

Disclosure shows appropriate joint filing and parent-subsidiary attribution; no governance action implied.

The Schedule 13G/A includes a joint filing agreement and an exhibit clarifying that Goldman Sachs & Co. LLC is a subsidiary of The Goldman Sachs Group, Inc. Itemized voting and dispositive powers show shared, not sole, authority, and the statement in the filing certifies the holdings are not intended to change or influence control. For governance review, this is a compliant, routine disclosure without material impact on board composition or control risks.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



THE GOLDMAN SACHS GROUP, INC.
Signature:Name: AMEEN SOETAN
Name/Title:Attorney-in-fact
Date:07/17/2025
GOLDMAN SACHS & CO. LLC
Signature:Name: AMEEN SOETAN
Name/Title:Attorney-in-fact
Date:07/17/2025
Exhibit Information

EXHIBIT (99.1) JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, the undersigned agree to the joint filing of a Statement on Schedule 13G (including any and all amendments thereto) with respect to the Common Stock, par value $ per share, of NEVRO CORP. and further agree to the filing of this agreement as an Exhibit thereto. In addition, each party to this Agreement expressly authorizes each other party to this Agreement to file on its behalf any and all amendments to such Statement on Schedule 13G. Date: 07/17/2025 THE GOLDMAN SACHS GROUP, INC. By:/s/ AMEEN SOETAN ---------------------------------------- Name: AMEEN SOETAN Title: Attorney-in-fact GOLDMAN SACHS & CO. LLC By:/s/ AMEEN SOETAN ---------------------------------------- Name: AMEEN SOETAN Title: Attorney-in-fact EXHIBIT (99.2) ITEM 7 INFORMATION The securities being reported on by The Goldman Sachs Group, Inc. ("GS Group"), as a parent holding company, are owned, or may be deemed to be beneficially owned, by Goldman Sachs & Co. LLC ("Goldman Sachs"), a broker or dealer registered under Section 15 of the Act and an investment adviser registered under Section 203 of the Investment Advisers Act of 1940. Goldman Sachs is a subsidiary of GS Group.

FAQ

How many NVRO shares does Goldman Sachs report owning?

1,172 shares beneficially owned, representing 0.0% of the class; shared voting power 905, shared dispositive power 1,172.

Does Goldman Sachs have sole voting power over NVRO shares?

No; the filing reports 0 shares with sole voting power and 905 shares with shared voting power.

Is this ownership intended to influence control of NVRO (NVRO)?

The filing states the securities are held in the ordinary course of business and were not acquired for the purpose of changing or influencing control.

Did Goldman Sachs file this Schedule 13G/A jointly?

Yes; The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC executed a joint filing agreement and filed jointly.

Is Goldman Sachs & Co. LLC identified as a subsidiary in the filing?

Yes; the filing states that Goldman Sachs & Co. LLC is a subsidiary of The Goldman Sachs Group, Inc.
Nevro Corp

NYSE:NVRO

NVRO Rankings

NVRO Latest News

NVRO Latest SEC Filings

NVRO Stock Data

189.98M
37.30M
Surgical and Medical Instrument Manufacturing
Surgical & Medical Instruments & Apparatus
Link
US
REDWOOD CITY